Le Lézard
Classified in: Health, Covid-19 virus
Subjects: PET, MRR

Global Veterinary Dermatology Drugs Market Analysis Report 2023: Market to Reach $28.69 Billion by 2030 - New Product Launches and Robust R&D Pipeline Boosts Market Prospects


DUBLIN, Oct. 31, 2023 /PRNewswire/ -- The "Veterinary Dermatology Drugs Market Size, Share & Trends Analysis Report By Indication, By Type, By Animal Type, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global veterinary dermatology drugs market is expected to reach USD 28.69 billion by 2030, registering a CAGR of 8.89% from 2023 to 2030

The market is driven by increasing pet expenditure, humanization of pets, robust R&D pipeline, launch of new products, the prevalence of dermatologic conditions, and initiatives by key companies.

For example, in June 2023, Zoetis received FDA clearance for Apoquel Chewable - the country's first and only chewable pharmaceutical for controlling allergic itch and inflammation in dogs. This expanded the company's portfolio and supported its growth objectives.

The COVID-19 pandemic and macroeconomic headwinds from 2020 to 2022 had both positive and negative impacts on the market. This included operational challenges, supply chain disruption, limited access to veterinary care, spike in pet adoption, adoption of telemedicine, and increased penetration of pet insurance.

Vimian for instance, reported dampened growth during Q1 2022 in its dermatology & specialty care segments due to volatility in shipments between quarters. By Q3 2022, the company reported robust growth in Dermatology & Specialty Care segments. Zoetis on the other hand witnessed volume growth of 14%, 3%, and 9% from in-line portfolio, including its dermatology products during Q2, Q3, and Q4 2021 respectively. In 2022, however, Zoetis reported 1-2% volume growth in its dermatology portfolio every quarter.

Ongoing research and development efforts in the field of veterinary dermatology have led to the creation of more effective and user-friendly drug formulations. These formulations are often easier to administer and can provide quicker relief for pets, ensuring medication compliance.

Growing initiatives by key market players is expected to propel the R&D pipeline and promote the launch of new products in the market. In May 2023, Dechra Pharmaceuticals PLC for example, partnered with ILC Therapeutics in Scotland to research and develop the latter's Caniferon product for the treatment of atopic dermatitis in dogs. This added to the company's product pipeline.

Veterinary Dermatology Drugs Market Report Highlights

Company Profiles

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Veterinary Dermatology Drugs Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Pet Ownership
3.2.1.2. Growing Number Of Clinical Trials Related To Veterinary Dermatology Drugs
3.2.1.3. Rising Incidence Rate Of Parasitic As Well As Other Skin Diseases In Animals
3.2.1.4. Investments By Market Players
3.2.2. Market Restraint Analysis
3.2.2.1. Lack Of Awareness In Developing Regions
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Veterinary Dermatology Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis
3.3.3. Pricing Analysis
3.3.4. Clinical Trial Analysis
3.3.5. Estimated Animal Population, by key countries, 2018 to 2022
3.3.6. COVID-19 Impact Analysis

Chapter 4. Veterinary Dermatology Drugs Market: Indication Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Veterinary Dermatology Drugs Market: Indication Movement Analysis & Market Share, 2022 & 2030
4.3. Parasitic Infections
4.4. Allergic Infections
4.5. Others

Chapter 5. Veterinary Dermatology Drugs Market: Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Veterinary Dermatology Drugs Market: Type Movement Analysis & Market Share, 2022 & 2030
5.3. Prescription
5.4. OTC

Chapter 6. Veterinary Dermatology Drugs Market: Animal type Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Veterinary Dermatology Drugs Market: Animal type Movement Analysis & Market Share, 2022 & 2030
6.3. Companion Animals
6.3.1. Companion Animals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. Dogs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3. Cats Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4. Horses Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Livestock Animals
6.4.1. Livestock Animals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. Cattle Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Veterinary Dermatology Drugs Market: Route of Administration Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Veterinary Dermatology Drugs Market: Route of Administration Movement Analysis & Market Share, 2022 & 2030
7.3. Topical
7.4. Oral
7.5. Injectable

Chapter 8. Veterinary Dermatology Drugs Market: Distribution Channel Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Veterinary Dermatology Drugs Market: Distribution Channel Movement Analysis & Market Share, 2022 & 2030
8.3. Hospital Pharmacies)
8.4. Retail
8.5. E-Commerce

Chapter 9. Veterinary Dermatology Drugs Market: Regional Estimates & Trend Analysis
9.1. Regional Outlook
9.2. Veterinary Dermatology Drugs Market: Regional Movement Analysis & Market Share, 2022 & 2030

Chapter 10. Competitive Landscape
10.1. Key Company Profiles
10.1.1. Participant's Overview
10.1.2. Indication Benchmarking
10.1.3. Financial Performance
10.1.4. Strategic Initiatives
10.2. Participant Categorization
10.3. Heat Map Analysis/ Company Market Position Analysis
10.4. Strategy Mapping
10.5. List of Other Key Market Players

For more information about this report visit https://www.researchandmarkets.com/r/6wfygc

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: